Browsing Tag
Redemplo
2 posts
From rare disease to mass market: plozasiran gets FDA green light for severe hypertriglyceridemia review
Arrowhead’s plozasiran receives FDA Breakthrough Therapy status for severe hypertriglyceridemia. Learn what this means for trials, patients, and the RNAi market.
How Arrowhead Pharmaceuticals’ first FDA-approved drug Redemplo could reshape treatment for familial chylomicronemia syndrome
Discover how Arrowhead Pharmaceuticals’ FDA approval for Redemplo could transform care for familial chylomicronemia syndrome.